title: Colon cancer after infliximab therapy for Crohn's disease.
abstract: Infliximab is an effective agent in the treatment of patients with Crohn's disease. Therapy with infliximab is generally well tolerated but there are concerns about its effects on the incidence of cancer. This case report refers to a 47-year-old patient with long-standing Crohn's disease, without a family history of colorectal cancer, who had a previous diagnosis of low-grade dysplasia that was not confirmed in subsequent studies, and was diagnosed with adenocarcinoma of the colon with peritoneal invasion after the fourth infusion of infliximab.
authors.affiliation: Gastroenterology Department, Hospital de São João, Porto, Portugal. fredericoferreira2@hotmail.com
authors.forename: Frederico
authors.initials: F
authors.lastname: Ferreira
authors.forename: Susana
authors.initials: S
authors.lastname: Lopes
authors.forename: Guilherme
authors.initials: G
authors.lastname: Macedo
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003106:Colon; D003110:Colonic Neoplasms / Q000209:etiology*; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab